Healthcare provider profile · identity verified

Linnea Williams, DO

Family Practice · RAYTOWN, MO · NPI 1770779530

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	498	190
Amlodipine Besylate	Amlodipine Besylate	275	96
Losartan Potassium	Losartan Potassium	270	89
Levothyroxine Sodium	Levothyroxine Sodium	230	72
Lisinopril	Lisinopril	220	86
Gabapentin	Gabapentin	197	80
Famotidine	Famotidine	177	58
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	168	46
Albuterol Sulfate Hfa	Albuterol Sulfate	160	73
Hydrochlorothiazide	Hydrochlorothiazide	140	54
Fluticasone Propionate	Fluticasone Propionate	131	56
Metoprolol Succinate	Metoprolol Succinate	124	47
Metoprolol Tartrate	Metoprolol Tartrate	121	36
Trazodone Hcl	Trazodone Hcl	100	29
Furosemide	Furosemide	98	34
Alvesco	Ciclesonide	91	36
Hydralazine Hcl	Hydralazine Hcl	91	31
Omeprazole	Omeprazole	83	37
Metformin Hcl	Metformin Hcl	81	34
Metformin Hcl Er	Metformin Hcl	80	33
Simvastatin	Simvastatin	77	25
Ibuprofen	Ibuprofen	74	33
Montelukast Sodium	Montelukast Sodium	72	26
Potassium Chloride	Potassium Chloride	70	18
Glipizide	Glipizide	68	26
Ozempic	Semaglutide	61	13
Atenolol	Atenolol	59	25
Tamsulosin Hcl	Tamsulosin Hcl	59	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	23
Rosuvastatin Calcium	Rosuvastatin Calcium	55	21
Pregabalin	Pregabalin	54	suppressed
Jardiance	Empagliflozin	53	19
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	52	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	51	suppressed
Baclofen	Baclofen	49	17
Amoxicillin	Amoxicillin	48	40
Ropinirole Hcl	Ropinirole Hcl	47	15
Alendronate Sodium	Alendronate Sodium	46	18
Pantoprazole Sodium	Pantoprazole Sodium	46	19
Cephalexin	Cephalexin	45	35
Sertraline Hcl	Sertraline Hcl	45	17
Duloxetine Hcl	Duloxetine Hcl	43	14
Tizanidine Hcl	Tizanidine Hcl	40	14
Alprazolam	Alprazolam	38	11
Hydroxyzine Hcl	Hydroxyzine Hcl	38	12
Allopurinol	Allopurinol	37	18
Breyna	Budesonide/Formoterol Fumarate	37	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	36	13
Propranolol Hcl	Propranolol Hcl	35	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	16
Prednisone	Prednisone	33	23
Wixela Inhub	Fluticasone Propion/Salmeterol	33	12
Clopidogrel	Clopidogrel Bisulfate	32	11
Escitalopram Oxalate	Escitalopram Oxalate	32	13
Oxycodone Hcl	Oxycodone Hcl	32	suppressed
Carvedilol	Carvedilol	30	11
Trospium Chloride	Trospium Chloride	30	13
Humulin N	Insulin Nph Human Isophane	29	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	28	25
Glipizide Er	Glipizide	27	12
Pravastatin Sodium	Pravastatin Sodium	27	12
Triamcinolone Acetonide	Triamcinolone Acetonide	27	15
Fluocinonide	Fluocinonide	26	11
Nortriptyline Hcl	Nortriptyline Hcl	26	11
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Hydrocortisone	Hydrocortisone	25	14
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	25	11
Buspirone Hcl	Buspirone Hcl	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Humalog Kwikpen U-100	Insulin Lispro	22	suppressed
Clobetasol Propionate	Clobetasol Propionate	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	21	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	21	suppressed
Lovastatin	Lovastatin	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Meloxicam	Meloxicam	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	13
Cholestyramine	Cholestyramine (With Sugar)	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Acyclovir	Acyclovir	16	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	16
Benazepril Hcl	Benazepril Hcl	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Colchicine	Colchicine	16	12
Doxycycline Monohydrate	Doxycycline Monohydrate	16	15
Finasteride	Finasteride	16	suppressed
Temazepam	Temazepam	16	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Erythromycin	Erythromycin Base	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	11
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	11
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Nystatin	Nystatin	14	suppressed
Ofloxacin	Ofloxacin	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Retin-A	Tretinoin	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Clindamycin Hcl	Clindamycin Hcl	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Naloxone Hcl	Naloxone Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Dexmethylphenidate Hcl Er	Dexmethylphenidate Hcl	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error